Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials

Nuria Kotecki, Nicolas Penel, Antoine Adenis, Charles Ferte and Stéphanie Clisant

PLOS ONE, 2012, vol. 7, issue 12, 1-4

Abstract: Background: The diagnosis of tumour progression or progressive disease (PD) is a key element for designing and interpreting contemporary phase II trials. In some cases, PD is stated by the physician and is not formally confirmed by imaging. Purpose: In this study, we intend to analyze the value of the PD based on clinical judgment and the risk of overestimating the occurrence of PD by clinical judgment. Methods: We have conducted a single-centre retrospective study to analyse the diagnostic accuracy of this clinical judgment compared to planned imaging including all patients enrolled in our institution in phase II trials investigating systemic treatments for advanced solid tumours between January 2008 and November 2010. Results: The positive predictive value (PPV) and the specificity of clinical judgment of PD was very high (>90%). Conclusions: According to this study, the clinical judgment of PD is highly predictive of radiological PD as assessed, for example, by RECIST. Physicians do not overestimate PD occurence. Clinical judgment of PD could be taken into account in the definition of PD.

Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052638 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 52638&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0052638

DOI: 10.1371/journal.pone.0052638

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().